Lutetium LU-177 Vipivotide Tetraxetan
Protein
Overview
Lutetium LU-177 Vipivotide Tetraxetan is a protein active pharmaceutical ingredient (ChEMBL CHEMBL4594406).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Lutetium LU-177 Vipivotide Tetraxetan expires 18 Sept 2041 and exclusivity 28 Mar 2028. Generic API sourcing typically opens up once these lapse.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.